(Q38794978)

6 September 2017

title

iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice (English)

1 reference

6 September 2017

0 references

Wang Qifan

1

1 reference

6 September 2017

Ning Fen

2

1 reference

6 September 2017

Xue Ying

3

1 reference

6 September 2017

Feng Xinwei

4

1 reference

6 September 2017

Du Jun

5

1 reference

6 September 2017

Zhang Ge

6

1 reference

6 September 2017

language of work or name

1 reference

11 February 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

37

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

10643-10652

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-016-4961-x

6 September 2017

exact match

0 references

cites work

Targeted cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Drug penetration in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Peptides for cell-selective drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Application of a proapoptotic peptide to intratumorally spreading cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Anti-cancer activity of targeted pro-apoptotic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Potential-dependent membrane permeabilization and mitochondrial aggregation caused by anticancer polyarginine-KLA peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Tumor-penetrating iRGD peptide inhibits metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Targeting of drugs and nanoparticles to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Imaging of integrin alphavbeta3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Design of model amphipathic peptides having potent antimicrobial activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Targeted delivery of a proapoptotic peptide to tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Targeting neuropilin-1 in human leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

The cell penetrating ability of the proapoptotic peptide, KLAKLAKKLAKLAK fused to the N-terminal protein transduction domain of translationally controlled tumor protein, MIIYRDLISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Electrical potentiation of the membrane permeabilization by new peptides with anticancer properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Cell death independent of caspases: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4961-X

Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma

21 January 2018

1 reference

12 December 2020

Neuropilin-1 expression in cancer and development

1 reference

12 December 2020

A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.

1 reference

12 December 2020

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

1 reference

12 December 2020

Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model.

1 reference

12 December 2020

Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study

1 reference

12 December 2020

Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin

1 reference

12 December 2020

10.1007/S13277-016-4961-X

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1015247778

0 references

1 reference